Q2 FY2026 EarningsQ2 FY26 significantly beat consensus across the board: revenue $103.5M vs. $86.2M expected, and EPS -$0.07 vs. -$0.41 expected. Core test volume growth of 32% YoY, primarily driven by the TissueCypher platform (+63.4% YoY), powered the top-line outperformance. Management raised FY26 revenue guidance to $365M-$375M (from $345M-$355M) and now expects to maintain positive Adjusted EBITDA through the second half of 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Castle Biosciences(CSTL) the Revenue is 103.55 M (+20.14%), Beat estimate;the EBIT is -3.07 M (+27.78%), Beat estimate;the EPS is -0.07 (-146.7%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.10B20.14%
0.09B0.06%
+0.02B20.08%
EBITExceed expectations
-0.00B27.78%
-0.02B252.92%
+0.01B280.70%
EPSExceed expectations
-0.07146.67%
-0.4067371.11%
+0.3367224.44%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf